InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,581.14
(
0.25%
)
US TECH 100
19,844.00
(
-0.01%
)
Dow Jones
39,614.22
(
0.61%
)
Brent Oil
85.55
(
-1.11%
)
Bitcoin
56,825.00
(
1.75%
)
Post# of 14687
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Rsarabjit

Send PM Follow Ignore
Followers 74
Posts 10119
Boards Moderated 0
Alias Born 02/01/2016

Rsarabjit

Re: None

Tuesday, 01/12/2021 9:58:48 AM

Tuesday, January 12, 2021 9:58:48 AM

Post# of 14687
GNBT - On January 6, 2021, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed to accept a One Hundred Thousand Dollar USD ($100,000.00) “Performance Guarantee Fee” payment to extend, for a second time, the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Performance Guarantee Fee Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement 
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up